Benzinga

Benzinga

Benzinga

domingo, septiembre 06

Dr Reddy's Laboratories Ltd

RDYNYSE
Trade with Public
Trade with Public
$11.97
-0.06-0.5%
al cierre: Sep 4, 5:00 PM EST
$11.97
N/A
After hour: Sep 4, 4:34 PM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoDividendosCompararOpcionesInforme de acciones

Dr Reddy's Laboratories Analyst Price Targets

Wall Street analyst price targets and consensus rating for Dr Reddy's Laboratories (RDY).

Price Target Range — 5 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingOverweight# Analysts2Avg. Consensus PT$17Upside to Avg. PT+41.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 5, 2025HSBCDamayanti Kerai UpgradeHold→Buy$14→$17
Nov 6, 2024BarclaysBalaji PrasadMaintainedOverweight$17→$17
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HSBC Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $16.9

HSBC analyst Damayanti Kerai upgrades Dr Reddy's Laboratories (NYSE:RDY) from Hold to Buy and raises the price target from $14.44 to $16.9.
Benzinga Newsdesk

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.
Vandana Singh

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $87

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $81 to $87.
Benzinga Newsdesk

Dr. Reddy's to Acquire Haleon's Nicotine Addiction Drug

Dr.
Zacks

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $81

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $80 to $81.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $80

Barclays analyst Balaji Prasad maintains Dr Reddy's Laboratories (NYSE:RDY) with a Overweight and raises the price target from $75 to $80.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved